News

Clinical Trials Arena10h

Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001

Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating ADI-001.
Clinical Trials Arena12h

First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525

Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked TCE.